How xylazine mixed with fentanyl changes the brain and withdrawal
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal
This project tests how adding xylazine to fentanyl changes brain signals and withdrawal for people who use fentanyl.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11322684 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are using lab models to see why xylazine added to fentanyl can make naloxone less effective and prolong the drug effects and withdrawal. They will study brain regions tied to reward and withdrawal and measure hundreds of signaling enzymes using advanced kinase-mapping technology. The team uses self-administration models and molecular analyses to find specific pathways that change when xylazine and fentanyl are combined. Findings will point to biological targets that could be used to counteract naloxone resistance or reduce harmful effects of the mix.
Who could benefit from this research
Good fit: People who use fentanyl, especially those exposed to or at risk for xylazine-adulterated fentanyl, would be most relevant to this research.
Not a fit: People without opioid use or those affected by unrelated medical conditions are unlikely to receive direct benefit from this specific work.
Why it matters
Potential benefit: If successful, this work could identify ways to restore naloxone effectiveness or new treatments that reduce overdose deaths when fentanyl is cut with xylazine.
How similar studies have performed: Prior opioid research has identified brain signaling targets for withdrawal, but studying xylazine’s role in naloxone resistance is relatively new and not yet well tested.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Gipson-Reichardt, Cassandra D — University of Kentucky
- Study coordinator: Gipson-Reichardt, Cassandra D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.